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Abstract
Background: Lymphatic vessels are major routes for metastasis in head and neck squamous cell
carcinoma (HNSCC), but lymphatic endothelial cells (LECs) are difficult to recognize in tumor
histological sections. D2-40 stains podoplanin, a molecule expressed in LECs, however, the
potential prognostic usefulness of this molecule is not completely understood in HNSCC. We
aimed to investigate the value of assessing peritumoral and intratumoral lymphatic vessel density
(LVD) as prognostic marker for HNSCC.
Methods: Thirty-one cases of HNSCC were stained for D2-40 and CD31. LVD and blood vessel
density (BVD) were assessed by counting positive reactions in 10 hotspot areas at ×200
magnification.
Results: D2-40 was specific for lymphatic vessels and did not stain blood vascular endothelial cells.
LECs showed more tortuous and disorganized structure in intratumoral lymphatic vessels than in
peritumoral ones. No statistical differences were observed between peritumoral-LVD and
intratumoral-LVD or between peritumoral-BVD and intratumoral-BVD. Tumor D2-40 staining was
positively associated with lymphatic vessel invasion (p = 0.011).
Conclusion: LVD is a powerful marker for HNSCC prognosis. We found significant differences in
peritumoral and intratumoral D2-40 immunoreactivity, which could have important implications in
future therapeutic strategies and outcome evaluation.
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Most of oral cavity cancers are squamous cell carcinomas
and, although they are accessible to biopsy and early iden-
tification, at the time of diagnosis, most of them have
already metastasized. Metastatic spread to regional lymph
nodes through the lymphatic system is one of the major
pathways by which head and neck squamous cell carci-
noma (HNSCC) disseminates. The mechanisms that
tumors use to metastasize are well documented concern-
ing the hematogenous spread, but lymphatic spread is not
so well understood. However, recent findings show its
importance in several human malignancies, including
HNSCC [1].
The study of lymphangiogenesis, growth and production
of new lymphatic vessels under several physiological and
pathological conditions has gained more attention in
recent years. Presently, there is no consensus whether the
major pathway of lymphatic spread is through the devel-
opment of lymphatic vessels intra or peritumorally, with
studies published supporting each of the possibilities
[2,3].
To understand the mechanisms underlying lymphangio-
genesis it is essential to understand how lymph vessels
develop and find specific markers for them. During
embryonic development endothelial cells express lym-
phatic vascular endothelial receptor (LYVE-1) and vascu-
lar endothelial growth factor receptor (VEGFR-3) and,
afterwards, the expression of the homeobox gene Prox1
commits these cells to the lymphatic lineage [4]. Members
of VEGF family are closely related to the lymphatic vessels
spread. Lymphangiogenesis largely depends on VEGFC
signalling and the activity of the receptor VEGFR3 [5,6].
Another molecule involved in this process is Podoplanin,
a transmembrane glycoprotein that may contribute to
lymphatic endothelial cell adhesion and migration and to
the formation of lymphatic connections [7].
In the last few years, specific lymphatic endothelial mark-
ers have been discovered, such as anti-LYVE-1 [8], anti-
Prox-1 [9], anti-VEGFR-3, anti-podoplanin [2] and D2-40
[10], which are able to stain lymphatic endothelial cells
(LECs). The recently discovered marker D2-40 was found
to be highly specific for LECs, not staining blood vessel
endothelial cells. Afterwards, it was also demonstrated
that D2-40 and anti-podoplanin had similar expression of
its antigens (M2A and podoplanin, respectively) in
human developing testis, testicular carcinoma in situ and
germ-cell tumors [11]. Evangelou compared both markers
and showed that they had similar specificity staining for
LECs [12] and, finally, Schacht et al reported that D2-40
recognized the same molecule as anti-podoplanin [13].
Presently, D2-40 is accepted as a marker for M2A antigen,
also called podoplanin, and it is known that besides LECs,
D2-40 is also expressed by other types of normal and neo-
plastic cells [10,14].
The aim of this study was to investigate the role of lym-
phatic vascular density (LVD) in a series of HNSCC and
evaluate whether intra or peritumoral LVD correlated with
the presence of lymph node invasion and distant metasta-
sis, and with patients clinical outcome. For that purpose,
D2-40 was used in due to of its higher specificity, as sug-
gested by Van den Eyden et al. [15], making it possible to
distinguish blood vascular density (BVD) from LVD, and
study its role in HNSCC dissemination. Finally, D2-40
staining of tumor cells was also evaluated, in order to
study the potential role of podoplanin in neoplasia devel-
opment and invasion.
Patients and methods
The material studied comprised formalin-fixed paraffin
embedded tissue samples from 31 previously untreated
patients with squamous cell carcinoma of the oral cavity.
Tumor sites included: 4 of the retromolar area, 10 of the
floor of mouth, 3 of the lower gingival area and 14 of the
oral tongue. All patients received local resection and elec-
tive lymph node neck dissection (unilateral or bilateral) at
Service of Head and Neck Surgery, Hospital Heliopolis,
Sao Paulo – Brazil. None of these patients had received
any drugs therapy before surgery. All patients had histo-
logically confirmed squamous cell carcinoma. Fourteen
patients received adjuvant postsurgical radiotherapy fol-
lowing the clinical protocol of the Hospital. These
patients were submitted to resection margins, positive
lymph nodes and/or perineural invasion. Additionally, all
patients have had at least 24 months of clinical follow up.
The group was constituted by patients with a median age
of 50 years (range, 38 – 70 years) and included 29 men
and 2 women. Of these, 29 had a prolonged smoking his-
tory and 26 had chronic alcohol consumption.
The distribution of patients was made according to the
post-surgery TNM classification based on the American
Joint Committee on Cancer (AJCC) and the Union Inter-
nationale Contre le Cancer (UICC) and the clinical classi-
fication was based on AJCC-UICC; additionally, the T, N,
and M characteristics are combined to produce a "stage"
of the cancer, from I to IVB [16].
D2-40 Immunohistochemical procedure
Immunohistochemistry was carried out using the avidin-
biotin-peroxidase complex assay, with the monoclonal
antibody D2-40 (DAKO Corporation, Carpinteria, CA,
USA). Briefly, deparaffinized and re-hydrated sections
were immersed in 0.01 M citrate buffer (pH 6.0) and
heated at 98°C for 20 min.; then slides were incubated
with 0.3 % hydrogen peroxide in methanol for 30 min.,
followed by incubation with Normal Horse Serum (Vec-Page 2 of 9
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perature, before incubating with the primary antibody
diluted 1:100, overnight at 4°C. Sections were sequen-
tially washed in PBS 1× and incubated with Biotinylated
Universal Secondary antibody (Vector Laboratories Inc.,
CA, USA) for 30 min., Vectastain® Elite ABC reagent (Vec-
tor Laboratories Inc., CA, USA) for 45 min. at 37°C, and
developed with 3,3'-diamino-benzidine (DAKO Corpora-
tion, Carpinteria, CA, USA) for 10 min. Negative controls
were performed by omitting the primary antibody and, as
positive control, tonsil tissue was used.
CD31 Immunohistochemical procedure
For CD31, the immunohistochemistry was carried out
with the streptavidin-biotin-peroxidase complex tech-
nique (Ultravision Detection System Anti-polyvalent,
HRP, Lab Vision Corporation, Fremont, CA, USA), using
specific primary antibody raised against CD31/PECAM-1
(rabbit monoclonal antibody, clone Ab-1/JC/70A, Neo-
markers, Freemont, CA, USA) diluted 1:50. Briefly, depar-
affinized and rehydrated sections were heated up to 98°C
for 20 min. in 0.01 M citrate buffer (pH 6.0). Endogenous
peroxidases were inactivated with 3 % hydrogen peroxide
in methanol for 10 min., followed by washing in PBS/
Tween. Tissue sections were incubated with blocking solu-
tion for 10 min. and incubated with the primary antibody
for 60 min. at room temperature. Sections were then
sequentially washed in PBS/Tween and incubated with
biotinylated goat anti-polyvalent antibody for 10 min.,
streptavidin peroxidase for 10 min., and developed with
3,3'-diamino-benzidine (DAB Substrate System; Lab
Vision Corporation, Fremont, CA) for 10 min. Appropri-
ated positive and negative controls were included in each
run. Negative controls were performed by omission of the
primary antibody and angiosarcoma was used as positive
control. The slides were counterstained with haematoxy-
lin and mounted with Synthetic Mountant Entellan
(Merck, Darmstadt, Germany).
Immunohistochemical evaluation
The immunohistochemical positive reaction of D2-40
and CD31 antibodies was evaluated considering its
expression in the cytoplasm of lymphatic and blood
endothelial cells, respectively. The evaluation was per-
formed blindly and both LVD and BVD were assessed as
postulated by Weidner et al [17], with slightly modifica-
tions. Microvessel was defined as a single endothelial cell
or a cluster of endothelial cells positive for D2-40 or
CD31, respectively, sitting around a visible lumen clearly
separate from adjacent microvessels and from other con-
nective tissue components. Additionally, as lymphatic
vessels could generally appear as distorted and overlapped
structures in cancer setting, the packed vessels were
assumed as one lymphatic unit. In contrary, blood vessels
commonly do not display distorted and packaged appear-
ance. The number of vessels was quantified at ×200 (×20
objective lens and ×10 ocular lens) magnification. A
median of 10 hot spot fields was defined as vessel density.
The examination of each hotspot corresponds to a
number of vessels confined to an area of 0.15 mm2. Both
D2-40 and CD31 immunohistochemical positive reac-
tions were independently counted in lymphatic and
blood vessels from intratumoral and peritumoral areas.
Intratumoral area was defined as the stromal tissue within
two or more neoplastic aggregates, and peritumoral area
was defined as the stroma tissue surrounding these neo-
plastic mass. D2-40 and CD31 positivity in tumor cells
was classified, considering immunoreaction extension as
negative (negative or weak immunoreaction) and positive
(moderate to strong immunoreaction). For evaluation of
lymphatic and blood vessels invasion, only D2-40 and
CD31 positive vessels occupied by neoplastic cells, respec-
tively, were considered. Seven cases were excluded for
CD31 evaluation due to technical limitations.
Statistical analysis
Data were stored and analyzed using the SPSS statistical
software (for Windows, version 14.0, Chicago, IL). The
Shapiro-Wilk test was applied to assess normality of the
results. Data was examined for statistical significance
using the T-Student, the One-Way ANOVA, the Mann-
Whitney U, the Kruskal-Wallis and the Pearson's chi-
square (χ2) tests, as appropriate, being threshold for sig-
nificance p values < 0.05.
Results
The comparison of vascular densities between peritu-
moral and intratumoral areas assessed by the lymphatic
marker D2-40 and blood vessels marker CD31 did not
show significant differences. Peritumoral-LVD and intra-
tumoral-LVD medians were 6.8 and 6.2 vessels in 10
hotspots, respectively (p = 0.488); and peritumoral-BVD
and intratumoral-BVD were 9.3 and 7.2 vessels per 10
hotspots, respectively (p = 0.299). Figures 1 and 2 show
representative immunoreactions for D2-40 and CD31,
respectively.
Table 1 depicts the significance of LVD and BVD related
with clinical -pathological data. Interestingly, BVD did
not correlate with classical parameters of tumor aggres-
siveness.
Remarkably, peritumoral LVD was correlated with a
shorter survival (p = 0.017; Figure 3).
Lymphatic invasion (Figure 4) was observed in 25 cases
with a statistical tendency to be associated with both peri
and intratumoral-LVD (p = 0.079 and p = 0.078, respec-
tively). Table 2 shows the correlation of both lymphaticPage 3 of 9
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parameters.
Perineural infiltration correlated with lymphatic invasion
superior than three vessels per case (p = 0.035) and worse
outcome was significantly more observed also in cases
with prominent lymphatic invasion (p = 0.039). Impor-
tantly, lymphatic invasion observed in more than 3 ves-
sels was associated with shorter survival (p = 0.003; Figure
5). This value was obtained with the median calculation
for lymphatic vessel invasion.
Poorly differentiated tumors present a tendency to invade
blood vessels (p = 0.077). Also, tumor recurrence was
more frequent in cases with blood vessel invasion (p =
0.013). No association between blood vessel invasion and
BVD was observed.
Some D2-40 immunoreaction was observed in epithelial
tumor cells (Figure 6), however, no statistical correlation
was observed between positive reactions of D2-40 in
tumors cells and the clinical-pathological parameters
(Table 2). D2-40 staining was positively associated with
All samples evaluated were found to have positive reaction to CD31, taining vascula  endothelial cells (black arrows)Figure 2
All samples evaluated were found to have positive reaction 
to CD31, staining vascular endothelial cells (black arrows). 
(×200).
Lymphatic vessels (black arrows) were specifically stained with D2-40, an antibody against podoplanin (A, B, C, D), that did not stain blood ve sels (arrow headFigure 1
Lymphatic vessels (black arrows) were specifically stained with D2-40, an antibody against podoplanin (A, B, C, D), that did not 
stain blood vessels (arrow head). A (×100), B (×200), C (×100), D (×200).Page 4 of 9
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lymphatic vessel invasion were positive for D2-40 expres-
sion in tumor cells while only 33.3 % of the negative cases
for lymphatic vessel invasion presented D2-40 expression
in tumor cells (p = 0.011).
Discussion
Nodal metastatic invasion is believed to be one of the
major predictors of HNSCC outcome [1,2]. It is still under
discussion whether lymphatic dissemination is through
lymphangiogenesis or through pre-existing lymphatics. It
has been shown, however, that the structure of lymphatic
vessels differs in these types of tumors, as they had a
higher number of lymphatic vessels, observed both intra-
tumorally and peritumorally [3]. In our study we
observed that lymphatic structure intratumorally was dis-
organized, with frequently tortuous or collapsed lumen
and that lymphatic invasion was present in most of the
samples. Together with the fact that HNSCC metastasize
frequently to lymph nodes, these findings support the
hypothesis that tumor lymphangiogenesis may be a fun-
damental pathway for neoplasia dissemination in
HNSCC [2].
Nevertheless, there is still some controversy whether the
major contributors are intratumoral or peritumoral lym-
phatic vessels. Franchi et al. [3] suggest that probably both
of them have a role in dissemination, but the relevance of
each one must be further assessed. In their study they
show a correlation between LVD peritumorally and
lymph node involvement. On the contrary, Kysas et al. [2]
show a correlation between LVD intratumorally and
lymph node involvement. It was observed that intratu-
moral LVD is composed by disorganized lymphatic ves-
sels which seriously limits the usefulness for an effective
conduit to metastization, comparing with the fully func-
tional peritumorally lymphatic vessels. Importantly, in
our series we observed that peritumoral LVD, but not
Table 1: Associations of LVD and BVD with the clinic-pathological data.
Peritumoral LVD* Intratumoral LVD¥ Peritumoral BVD* Intratumoral BVD*
n Median p n Mean p n Median p n Median p
Age 1.000 0.569 0.590 0.266
Gender 0.560 0.743 ---- ----
Smoking history 0.533 0.295 0.532 0.250
Alcohol 
consumption
0.867 0.502 0.773 0.896
Mouth region 0.454 0.118 0.845 0.495
Retromolar 4 6.2 4 7.8 4 8.1 4 4.6
Oral floor 10 5.2 10 5.3 8 8.0 7 8.3
Lower gingiva 3 7.1 3 7.9 3 10.2 3 15.9
Tongue 13 7.5 14 6.4 11 9.7 10 7.4
Histological 
Differentiation
0.629 0.526 0.987 0.711
Desmoplasia 0.986 0.869 0.288 0.085
Perineural 
infiltration
0.780 0.721 0.833 0.538
T 0.491 0.443 1.000 0.567
pT1 + pT2 11 7.0 12 6.0 9 8.7 7 6.9
pT3 + pT4 19 6.7 19 6.6 17 8.7 17 7.6
N 0.722 0.767 0.085 0.202
pN0 + pN1 17 7.0 17 6.3 14 6.7 13 6.9
pN2 + pN3 13 6.7 14 6.5 12 9.6 11 7.6
Clinical Staging 0.423 0.998 0.652 0.819
Metastasis 0.717 0.159 0.355 0.698
Absent 25 6.5 26 6.6 22 9.0 20 7.4
Present 5 7.1 5 5.1 4 6.5 4 6.0
Local recurrence 0.052 0.618 0.544 0.874
Negative 22 6.5 22 6.3 19 8.4 17 7.5
Positive 8 8.4 9 6.7 7 9.7 7 7.2
Outcome 0.083 0.859 0.314 0.052
Disease free 14 6.0 14 6.2 11 6.9 10 7.2
Death for other
reasons
3 8.7 3 6.6 3 10.2 3 15.9
Death by cancer 13 7.8 14 6.6 12 9.0 11 5.8
* Mann-Whitney U test and Kruskal-Wallis test when k > 2; ¥ T-Student test and One-Way ANOVA when k > 2)Page 5 of 9
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rence, which could reinforce the hypothesis that peritu-
moral lymphatic vessels are competent to participate in
the neoplastic escape. We also observed that cases where
the tumor cells invaded more than three lymphatic vessels
strongly correlated with perineural invasion and poor
clinical outcome. This is important because perineural
invasion is a phenomenon that may affect the therapeutic
decision making in dealing with head and a neck cancer
and its occurrence is believed to be a remarkable sign of
tumor aggressiveness [18].
Because D2-40 is being used mainly as a lymphatic vessel
marker, staining of other cells rather than LECs is impor-
tant to be distinguished to minimize errors in quantifica-
tion of LVD. Besides that, it could also give new clues to
understand the functions and importance of podoplanin.
Franchi et al. reported no staining of tumor cells in their
HNSCC samples [3]. On the contrary, we found that D2-
40 stained the majority of the tumor cells (n = 23 or 74%)
in HNSCC samples evaluated in this study. Concordantly
with our observation, there is also data showing that D2-
40 actually stains carcinomas and other malignancies
[10,13,14]. It was reported that D2-40 is specific for M2A
region of podoplanin, a molecule found to be overex-
pressed in some tumors cells [13]. These data together
with the knowledge about the role of podoplanin in
cytoskeleton reorganization, leads us to believe that podo-
planin might play a role in neoplastic development, as
previously proposed by Schacht et al. [13]. Supporting this
hypothesis, Wicki et al. [19] showed, using an experimen-
tal mice model, that overexpression of podoplanin
induces cellular alterations resulting in increased cellular
migration. In accordance to our results, they also observed
a peripheric tumoral staining pattern. Based on these find-
ings, they suggested that podoplanin might in fact play a
pivotal role in a novel molecular pathway of collective cell
migration independently from other processes such as
cadherin switch and epithelial-mesenchymal transition
[19]. Dumoff and colleagues [20] recently reported that
low immunoreactivity for D2-40 in tumor cells correlates
with lymphatic invasion and nodal metastasis in squa-
mous cell carcinoma of the uterine cervix. In spite of these
evidences, we did not find significant differences in D2-40
positive reaction in tumor cells and the clinical parame-
ters of cancer prognosis. Against to some evidences docu-
mented in cervical cancer [21], we found that D2-40
positive reaction in tumor cells correlates with lymphatic
invasion, but not with lymph node invasion, corroborat-
ing just in part the findings recently reported by Yuan and
co-workers [22]. These authors suggested that podoplanin
may play a role in promoting the spread of tumor cells
through lymphatic vessels because podoplanin-express-
ing tumor cells were also observed inside lymphatic ves-
sels; additionally, they also observed the tumor cells
expressing high levels of podoplanin even in regional
lymph nodes. Presently, these interesting findings were
not corroborated by our observations. We actually
observed that positive D2-40 decorating malignant cells
and LVD highlighted by D2-40 staining both are associ-
Survival rates related with peritumoral LVDFigure 3
Survival rates related with peritumoral LVD.Page 6 of 9
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of these contradictory observations is not currently recog-
nized. However, two motivating studies have demon-
strated that lymphatic markers were differentially
expressed by LECs from different organs, which indicate a
clear phenotypic heterogeneity [23]; and that lymphang-
iogenesis in oral SCC vary depending on the region within
the tumor tissue [24]. Accordingly, we can hypothesize
that tumor cells of same histological pattern could also
differently express podoplanin according to the organ
where the neoplasia grows.
Conclusion
our results demonstrate that D2-40 can be considered a
useful marker to predict HNSCC aggressiveness because
peritumoral LVD and D2-40 positive reaction in cancer
cells, both highlighted with D2-40 positive staining, were
strongly associated with lymphatic vessel invasion and
clinical parameters of worse prognosis.
Table 2: Association of lymphatic and blood vessels invasion, as well as positive D2-40 immunoreaction in tumor cells, with the clinic-
pathological data.
Lymphatic 
invasion
Lymphatic 
invasion > 3
Blood vessel invasion D2-40 positivity in 
tumor cells
n % p % p n % p n % p
Age 0.056 0.886 0.157 0.474
> 50 15 66.7 40.0 13 0.0 15 80.0
≤ 50 16 93.8 37.5 14 14.3 16 68.8
Gender 0.474 0.066 0.773 0.419
Female 2 100.0 100.0 1 0.0 2 50.0
Male 29 79.3 34.5 26 7.7 29 75.9
Smoking history 0.257 0.245 0.678 0.419
Alcohol consumption 0.232 0.038 0.603 0.746
No 5 100.0 80.0 3 0.0 5 80.0
Yes 26 76.9 30.8 24 8.3 26 73.1
Mouth region 0.472 0.317 0.853 0.653
Differentiation 0.111 0.968 0.077 0.982
Well differentiated 7 57.1 42.9 6 0.0 7 71.4
Moderate differentiated 16 93.8 37.5 13 0.0 16 75.0
Poor differentiated 8 75.0 37.5 8 25.0 8 75.0
Desmoplasia 0.724 0.909 0.313 0.867
Perineural infiltration 0.283 0.035 0.693 0.319
Negative 20 75.0 25.0 17 5.9 20 80.0
Positive 11 90.9 63.6 10 10.0 11 63.6
T 0.763 0.625 0.299 0.935
N 0.791 0.756 0.189 0.253
Clinical Staging 0.998 0.640 0.467 0.294
Metastasis 0.232 0.286 0.540 0.746
Tumor recurrence 0.457 0.675 0.013 0.540
Negative 22 77.3 36.4 20 0.0 22 77.3
Positive 9 88.9 44.4 7 28.6 9 66.7
Outcome 0.290 0.039 0.259 0.867
Disease free 14 71.4 14.3 12 0.0 14 78.6
Dead for other reasons 3 66.7 66.7 3 0.0 3 66.7
Dead by the cancer
consequences
14 92.9 57.1 12 16.7 14 71.4
Lymphatic invasion = any number of invaded lymphatic vessel. Lymphatic invasion > 3 = this number represents a median value.
Invasion of lymphatic vessels was found, with tumor cells i side the lumen of the lymphaticsFigure 4
Invasion of lymphatic vessels was found, with tumor cells 
inside the lumen of the lymphatics. (×200).Page 7 of 9
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